Estée Lauder's growth mix is improving, but recovery expectations are largely reflected in the valuation

Overview

The report assesses whether Estée Lauder's more balanced growth in F4Q26 is sufficient to support a more optimistic FY27 earnings outlook and valuation. Barclays believes the transformation is beginning to work and that makeup, Mainland China, and Asia-Pacific can provide multiple growth drivers, but underlying North American demand remains insufficiently proven and the current valuation already reflects substantial recovery expectations. It therefore maintains its Equal Weight rating.

Core views

The central change in F4Q26 was that the sources of growth became genuinely broad-based for the first time. During the seven quarters since Estée Lauder launched its transformation, total company sales had exceeded expectations slightly on several occasions, but the upside had generally been concentrated in only a few markets or categories. This quarter, incremental growth came simultaneously from the Americas, Asia-Pacific, travel retail, skin care, makeup, and fragrance. The report believes this indicates that the Beauty Reimagined strategy's efforts to reduce reliance on skin care and China while broadening brand and regional exposure are beginning to work. However, the Americas' reported 5% growth was supported by one-time benefits and the timing of Prime Day shipments. Barclays estimates that underlying growth after excluding these factors was approximately 1%, which was still better than its forecast but far below the recently accelerating growth rate of the prestige beauty market. The more balanced growth was also evident in Mainland China and market share. Mainland China sales grew 9% in FY26, comprising high-single-digit growth in skin care, mid-single-digit growth in makeup, and double-digit growth in fragrance, showing that the China market is no longer driven solely by skin care. Estée Lauder grew 3% overall in FY26, while the prestige beauty market grew 2% to 3% according to the company, meaning that overall market share was maintained or improved slightly. Barclays also cautions that this market growth measure is lower than the levels discussed by other beauty companies. The company gained value share in Mainland China and Japan in both F4Q26 and the full year, and returned to value-share growth in South Korea and Western Europe in F4Q26; the United Kingdom was driven by skin care and fragrance. The United States has not yet returned to value-share growth, but achieved volume-share gains in every quarter and every category during FY26. The company expects the global prestige beauty market to grow at least 3% to 4% in FY27. Barclays models company revenue growth of approximately 4%, implying overall share performance similar to FY26 in the base case, while the upper end of guidance would require broader share gains. The central theme for FY27 is the simultaneous operation of multiple growth engines, though the level of certainty differs among them. Barclays expects growth to accelerate in North America and makeup, while Asia-Pacific and Mainland China remain strong. Its North American F1Q27 growth forecast is 3%, and management stated that July trends were strong, driven mainly by Clinique and MAC's performance in social-commerce channels such as TikTok Shop. However, the report believes much of the recent growth may have resulted from the shipment timing of new product launches across categories, while actual consumer sell-through and new-product acceptance remain to be seen. By comparison, the improvement in makeup has more continuous supporting evidence: the category improved from a 1.5% decline in F1H26 to flat growth in F3Q26 and 2% growth in F4Q26. MAC delivered low-single-digit growth, while Tom Ford delivered double-digit growth. MAC is also benefiting from entering selected Sephora stores in the United States, social-commerce growth, and strong global performance from new products such as lip gloss. The report believes it may also benefit from the 1990s nostalgia trend. Barclays raises its FY27 organic sales growth forecast by 30 basis points to 4.1%, comprising approximately 4.5% growth in F1H27 and approximately 3.8% in F2H27, with the first half itself weighted toward F1Q27: F1Q and F2Q are expected to grow 5% and 4%, respectively. On earnings, the company's better-than-expected quarterly performance and additional selling, general, and administrative expense leverage from PRGP prompt Barclays to raise its FY27 operating margin forecast from 13.0% to 13.3%, near the upper end of the company's 12.7% to 13.5% guidance range. The FY27 adjusted EPS forecast rises from USD 3.08 to USD 3.31, also near the upper end of the USD 3.10 to USD 3.35 guidance range. The report emphasizes that the increases in the margin and EPS forecasts derive more from PRGP savings than from stronger operating leverage. Because management explicitly plans to reinvest additional benefits in consumer-facing activities, further EPS upside will require sales growth to exceed expectations rather than relying solely on cost savings. The medium-term model shows operating improvement outpacing revenue growth: revenue rises from USD 15.062bn in 2026A to USD 17.214bn in 2029E, a 4.6% CAGR; adjusted EBITDA rises from USD 2.483bn to USD 3.669bn, a 13.9% CAGR; adjusted EBIT rises from USD 1.687bn to USD 2.757bn, a 17.8% CAGR; adjusted net income rises from USD 915mn to USD 1.610bn, a 20.7% CAGR; and adjusted EPS rises from USD 2.51 to USD 4.39, a 20.5% CAGR. The adjusted EBIT margin is expected to rise from 11.2% to 16.0%, while ROIC increases from 8.0% to 10.9%. Free cash flow is forecast at USD 1.316bn in 2026A, USD 782mn in 2027E, USD 1.395bn in 2028E, and USD 1.699bn in 2029E. Net debt declines from USD 3.808bn in 2026A to USD 2.135bn in 2029E, but temporarily rises to USD 4.094bn in 2027E. Despite the forecast increases, Barclays believes the valuation is already close to full. Following the earnings report, the shares rose 16% in one day, while the S&P 500 rose 0.2%. The report views this reaction as somewhat exuberant, though it understands that the market would reward a revenue-driven earnings beat and growth guidance weighted toward F1H27. According to the report's estimates, the current share price implies 27.5x CY27 EPS and a 21% premium to beauty peers, which represents a fair valuation. The new USD 97 price target is based on updated CY27 EPS of USD 3.56 and a P/E multiple of 27.2x, assuming a 20% premium to global beauty peers and a 5% premium to L'Oréal. The previous USD 80 price target was based on CY27 EPS of USD 3.48 and a P/E multiple of approximately 23x, with only a 10% premium to global beauty peers. The rationale for the higher premium is Estée Lauder's accelerating revenue growth relative to FY26 and its higher earnings growth than peers over the next twelve months. The scenario analysis further explains why the rating remains neutral. The upside scenario assumes stronger-than-expected sales growth and corresponding margin expansion, using a P/E multiple of approximately 29.5x and CY27 EPS of USD 4.09. The downside scenario assumes a further slowdown in China and a longer-than-expected travel retail recovery, using a P/E multiple of 22.7x and CY27 EPS of USD 3.25, corresponding to USD 74. Barclays recognizes the direction of the transformation but believes an adjustment of this scale is unlikely to progress linearly. If the market once again prices in longer-term earnings power in advance while the company chooses to reinvest upside in growth, actual profit delivery may fall below the level implied by the bull-case scenario.

Analysis framework

Barclays first compares actual F4Q26 sales performance with its prior forecast and excludes one-time benefits and shipment-timing effects to distinguish reported growth from underlying growth. It then examines growth by region, category, brand, and market share to determine whether it is genuinely diversified. Based on this analysis, the report adjusts its quarterly FY27 sales, margin, and EPS models, distinguishing the contributions from revenue growth, operating leverage, and PRGP cost savings. Finally, it derives the price target using CY27 EPS and a P/E premium relative to global beauty peers and tests the valuation range through upside, base, and downside scenarios.

Methodology notes

• Valuation MethodPE/PEG valuation

  Relative P/E valuation based on CY27 EPS

  The report multiplies updated CY27 EPS of USD 3.56 by a 27.2x P/E multiple to derive a USD 97 price target. Premiums of 20% to global beauty peers and 5% to L'Oréal express its valuation recognition of Estée Lauder's recovery pace and earnings growth.

• (Out-of-Vocabulary Method)

  Upside and downside scenario analysis

  The report varies assumptions for sales growth, margins, the China market, and the travel retail recovery, applying different CY27 EPS estimates and valuation multiples to show the potential valuation range if operating results deviate from the base forecast.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• The Estée Lauder Companies (EL)

  The U.S.-listed company directly covered by the report; the central view is that its growth mix is improving, but its valuation is already close to full.

  Strengths

  F4Q26 growth spanned multiple regions and categories; Mainland China, Asia-Pacific, and makeup performance improved; more markets returned to share growth; PRGP savings support higher margin and EPS forecasts.

  Weaknesses

  Reported North American growth was supported by one-time benefits and shipment timing, with underlying growth of only approximately 1%; the transformation is extensive and unlikely to progress linearly; the United States has not yet returned to value-share growth.

  Comparison

  The current share price implies 27.5x CY27 EPS, a 21% premium to beauty peers; the price target assumes a 20% premium to global beauty peers and a 5% premium to L'Oréal.

  Risks

  Growth in China may slow further, the travel retail recovery may be delayed, new-product shipments may not translate into consumer sell-through, and additional profits may be reinvested in growth.

Key data

• RatingEQUAL WEIGHTMaintained; industry view is NEUTRAL
• Price TargetUSD 97.00Raised 21% from USD 80.00
• Reference Share PriceUSD 98.01August 19, 2026; 52-week range of USD 121.64 to 66.22
• Post-Earnings Share Price PerformanceEL +16%; S&P 500 +0.2%The report considers the reaction somewhat exuberant
• Americas F4Q26 Growth+5%Underlying growth is estimated at approximately 1% after excluding one-time benefits and Prime Day shipments
• Mainland China FY26 Growth+9%High-single-digit growth in skin care, mid-single-digit growth in makeup, and double-digit growth in fragrance
• FY26 Company and Market GrowthEstée Lauder +3%; prestige beauty market +2% to +3%The company's overall market share was maintained or improved slightly
• FY27 Global Prestige Beauty Market OutlookAt least +3% to +4%Company expectation
• Makeup Growth TrendF1H26 -1.5%; F3Q26 flat; F4Q26 +2%Continuous improvement; MAC grew at a low-single-digit rate and Tom Ford at a double-digit rate
• FY27 Organic Sales Growth Forecast+4.1%Raised by 30 basis points; F1H27 approximately +4.5% and F2H27 approximately +3.8%
• FY27 Quarterly Growth ForecastF1Q +5%; F2Q +4%Growth is expected to be weighted toward the first half; North American F1Q growth is forecast at 3%
• FY27 Operating Margin Forecast13.3%Raised from 13.0%; company guidance is 12.7% to 13.5%
• FY27 Adjusted EPS ForecastUSD 3.31Raised from USD 3.08; company guidance is USD 3.10 to 3.35
• Revenue Forecast2026A USD 15,062mn; 2027E 15,707mn; 2028E 16,404mn; 2029E 17,214mn4.6% CAGR from 2026A to 2029E
• Adjusted EBITDA Forecast2026A USD 2,483mn; 2027E 2,924mn; 2028E 3,316mn; 2029E 3,669mn13.9% CAGR
• Adjusted EPS Forecast Series2026A USD 2.51; 2027E 3.31; 2028E 3.79; 2029E 4.3920.5% CAGR
• Adjusted EBIT Margin2026A 11.2%; 2027E 13.3%; 2028E 14.9%; 2029E 16.0%Profitability is expected to continue recovering
• ROIC2026A 8.0%; 2027E 9.4%; 2028E 10.1%; 2029E 10.9%Returns on capital improve each year
• Free Cash Flow2026A USD 1,316mn; 2027E 782mn; 2028E 1,395mn; 2029E 1,699mnDeclines initially in 2027E, then recovers
• Base-Case Price Target Valuation27.2x CY27 P/E; CY27 EPS USD 3.56Assumes a 20% premium to global beauty peers and a 5% premium to L'Oréal
• Current Valuation27.5x CY27 P/EA 21% premium to beauty peers
• Upside ScenarioApproximately 29.5x P/E; CY27 EPS USD 4.09Assumes both sales growth and margin expansion exceed expectations
• Downside ScenarioUSD 74.00; 22.7x P/E; CY27 EPS USD 3.25Assumes a further slowdown in China and a delayed travel retail recovery

Impact & implications

The report believes Estée Lauder has shifted from a growth model dependent on China and skin care to one jointly driven by more regions, categories, and brands, strengthening the operating foundation of its transformation. However, North American growth remains affected by one-time factors and shipment timing, while the earnings forecast increase also derives more from cost savings. Because the current share price already incorporates a high peer premium, further valuation expansion will require sales, consumer sell-through, and market share to continue exceeding expectations.

Risks

• A further slowdown in the China market would weaken the currently more balanced regional growth mix.
• The travel retail recovery may take longer than expected.
• Recent North American growth has been significantly supported by one-time benefits and shipment timing, and sustained sell-through of new products remains uncertain.
• The large-scale transformation may not proceed linearly, and operating performance may continue to fluctuate periodically.
• The company may reinvest better-than-expected benefits in consumer-facing activities, causing longer-term profits to fall below the level implied by the market's bull-case scenario.
• If the share price prices in unrealized longer-term earnings power prematurely, the valuation may once again move ahead of fundamentals.

What to watch

• Track underlying North American growth after excluding one-time factors and shipment timing, as well as consumer sell-through of new products.
• Monitor whether makeup can sustain its improvement from a 1.5% decline in F1H26 to 2% growth in F4Q26.
• Watch MAC's performance at Sephora, in social commerce, and with new products, as well as whether Tom Ford can sustain double-digit growth.
• Track market share changes in Mainland China, Asia-Pacific, travel retail, South Korea, and Western Europe.
• Monitor whether FY27 growth is concentrated in the first half as forecast and whether F1Q and F2Q can achieve growth of 5% and 4%, respectively.
• Watch how PRGP savings, selling, general, and administrative expense leverage, and consumer-facing reinvestment affect the potential for EPS upside.